US Biotechnology and Pharmaceuticals: The Biopharma 2026 halftime report: More to like coming down the pike

研报英文原文证据摘录

US Biotechnology and Pharmaceuticals: The Biopharma 2026 halftime report: More to like coming down the pike

US Biotechnology and Pharmaceuticals

16 June 2026 Citi Research

Figure 5. Top 2H26 Biopharma Catalysts

Event Category Company Product Indication Event Description

Hidradenitis

Trial Readout AbbVie Lutikizumab Phase 3, 2H26

Suppurativa

Trial Readout AbbVie Rinvoq Phase 3, 2H26

Etentamig

3L Multiple

Trial Readout AbbVie monotherapy Phase 3

Myeloma

(CERVINO)

Clinical update Amgen MariTide Type 2 diabetes MariTide full data 2026

Trial Readout Amgen Dazodalibep Sjogren's Phase 3, 2H26

Eosinophilic

Trial Readout Amgen Tezspire Phase 3, 2H26

Esophagitis

Systemic Lupus

Trial Readout Biogen Litifilimab Phase 3 TOPAZ-1/2, 4Q26

Erythematosus

Stroke, atrial

Clinical update Bristol Milvexian LIBREXIA-AF and LIBREXIA-STROKE data in 2026

fibrillation

Alzheimer's

Clinical update Bristol Cobenfy ADEPT data readout

psychosis

Clinical update Bristol Pumitamig solid tumors Early stage data

2L Metastatic

Trodelvy

Trial Update Gilead Endometrial Phase 3 update

ASCENT-GYN

Cancer

Trodelvy 1L mNSCLC (PD-L1

Trial Update Gilead Phase 3 update

EVOKE-03 high)

Clinical update Lilly Retatrutide Weight loss TRIUMPH-3 data 2Q26, TRIUMPH-2 data mid-2026

Trial Readout Lilly Retatrutide Weight Loss Phase 3 TRIUMPH-2/3/5, 2H26

Trial Readout Lilly Retatrutide Type 2 Diabetes Phase 3 TRANSCEND-T2D 2/3, 2H26

Obstructive Sleep

Trial Readout Lilly Orforglipron Phase 3 ATTAIN-OSA, 4Q26

Apnea

Clinical update Merck Tulisokibart UC, SS-ILD, HS Assorted tulisokibart readouts in 2026

Sigvotatug 2L+ Non-

Trial Readout Pfizer vedotin (PF- squamous Phase 2, 2H

08046047) Metastatic NSCLC

Berobenatide +

Trial Readout Pfizer Amylin Analog N/A Phase 1/2, 2H

Combo

mCRPC Post